open access

Vol 49, No 2 (2018)
SHORT COMMUNICATION
Published online: 2018-08-30
Submitted: 2018-11-27
Get Citation

Przewlekłe leczenie przeciwkrzepliwe

Krystyna Zawilska
DOI: 10.2478/ahp-2018-0009
·
Acta Haematol Pol 2018;49(2):47-49.

open access

Vol 49, No 2 (2018)
SHORT COMMUNICATION
Published online: 2018-08-30
Submitted: 2018-11-27

Abstract

Unprovoked venous thromboembolism (VTE) - proximal venous thrombosis or pulmonary embolism - should be treated either 3 months or indefinitely if the risk of bleeding is low. This article summarizes the efficacy and safety of extended therapy of VTE with direct oral anticoagulants (DOAC) in comparison with warfarin, as well as the role of of acetylsalicylic acid (ASA) for the long-term prevention of recurrent VTE. As the Survet study showed, for some patients who have already completed at least 6 months of anticoagulant treatment for their index VTE event, an oral glycosaminoglycan - sulodexide associated with compression therapy is a good choice, because it decreases the incidence of recurrences of VTE without detectable risks for the patients’ safety.

Abstract

Unprovoked venous thromboembolism (VTE) - proximal venous thrombosis or pulmonary embolism - should be treated either 3 months or indefinitely if the risk of bleeding is low. This article summarizes the efficacy and safety of extended therapy of VTE with direct oral anticoagulants (DOAC) in comparison with warfarin, as well as the role of of acetylsalicylic acid (ASA) for the long-term prevention of recurrent VTE. As the Survet study showed, for some patients who have already completed at least 6 months of anticoagulant treatment for their index VTE event, an oral glycosaminoglycan - sulodexide associated with compression therapy is a good choice, because it decreases the incidence of recurrences of VTE without detectable risks for the patients’ safety.

Get Citation

Keywords

Extended therapy of venous thromboembolism; VTE; direct oral anticoagulants; DOAC; acetylsalicylic acid; ASA; glycosaminoglycan

About this article
Title

Przewlekłe leczenie przeciwkrzepliwe

Journal

Acta Haematologica Polonica

Issue

Vol 49, No 2 (2018)

Pages

47-49

Published online

2018-08-30

DOI

10.2478/ahp-2018-0009

Bibliographic record

Acta Haematol Pol 2018;49(2):47-49.

Keywords

Extended therapy of venous thromboembolism
VTE
direct oral anticoagulants
DOAC
acetylsalicylic acid
ASA
glycosaminoglycan

Authors

Krystyna Zawilska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl